Sanofi SA has synthesized new cyclopropane-aryl and vinyloxy-aryl compounds acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or WW domain-containing transcription regulator protein 1 (WWTR1; TAZ)/TEAD interaction inhibitors potentially useful for the treatment of cancer.